Alopecia areata is more prevalent in patients with IBD, especially those on anti-TNF therapy, compared with controls. The study found no significant difference in alopecia improvement between those ...

Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...

In a propensity score-matched analysis including 754 patients ages 50 and up, use of vedolizumab was associated with a 45.4% risk of treatment failure -- defined as a composite risk of IBD-related ...

Use of lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) to predict relapse in patients with diffuse large B-cell lymphoma (DLBCL). Background: Inflammatory bowel disease ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Vedolizumab and ustekinumab associated with a lower risk for infection-related hospitalizations ...

Patients with inflammatory bowel disease (IBD) taking ustekinumab (Stelara) are less likely to have infections as a side effect than those taking tofacitinib (Xeljanz) or anti–tumor necrosis ...

Patients with rheumatoid arthritis (RA) who used tumor necrosis factor (TNF) inhibitors had significantly higher rates of nonmelanoma skin cancer and non-Hodgkin lymphoma. A new report based on ...

Patients with inflammatory bowel disease (IBD) face a higher risk for complications of herpes zoster than those without IBD, with older age, higher comorbidity scores, and management with anti–tumor ...